Company stands out in Ethics, Environment, and Labor and Human Rights focus areas for 2024 pls logo Pace Life Sciences logo ...

How Technology is Reshaping Aesthetic Medicine and Expanding Patient Options NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / The field of cosmetic medicine is evolving at an unprecedented pace, ...

ORLANDO, FL / ACCESS Newswire / April 1, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is ...

Pharmaceutical Market Size & TrendsGlobal size of the pharmaceutical market was at USD 1,645.75 billion in 2024 and is ...

Investment/MiscellaneousM1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment01-Apr-2025 / 17:13 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of ...

Four Industry Veterans Unite to Replace Single-Use Plastics with High-Performance Pulp Products DAYTON, OHIO / ACCESS Newswire / April 1, 2025 / PulpFixin, a groundbreaking company dedicated to ...

Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...

Flexible PBM implements an AI-powered platform to reduce specialty drug costs while improving patient care. MILWAUKEE, WISCONSIN / ACCESS Newswire / April 1, 2025 / Serve You Rx, a full-service ...

SALT LAKE CITY, UTAH / ACCESS Newswire / April 1, 2025 / CenExel, a leading clinical research site network, has launched a new mobile application designed to make it easier for patients to find and ...

CDMO, has appointed Dr James Miskin as Non-Executive Director. James brings extensive experience in the cell and gene therapy sector, following a 23-year tenure at Oxford Biomedica. He oversaw ...

OPEN Health Group is pleased to announce the appointment of Matt D’Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of experience in medical affairs and ...

Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical ...